Highlights on Molecular Mechanisms of MDSC-Mediated Immune Suppression: Paving the Way for New Working Hypotheses

REFERENCES

• Al-Shami, A., Mahanna, W., and Naccache, P.H. (1998). Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. J. Biol. Chem. 273:1058–1063.
   PubMed Web of Science ®Google Scholar
• Brandau, S., Trellakis, S., Bruderek, K., Schmaltz, D., Steller, G., Elian, M., Suttmann, H., Schenck, M., Welling, J., Zabel, P., and Lang, S. (2011). Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89:311–317.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Chappell, D.B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., Restifo, N.P. (1999). Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:5728–5737.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Cingarlini, S., Marigo, I., De Santo, C., Gallina, G., Dolcetti, L., Ugel, S., Peranzoni, E., Mandruzzato, S., and Zanovello, P. (2006). Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol. Invest. 35:327–357.
   PubMed Web of Science ®Google Scholar
• Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5:641–654.
   PubMed Web of Science ®Google Scholar
• Bunt, S.K., Yang, L., Sinha, P., Clements, V.K., Leips, J., and Ostrand-Rosenberg, S. (2007). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67:10019–10026.
   PubMed Web of Science ®Google Scholar
• Cheng, P., Corzo, C.A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M.M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., Roth, J., and Gabrilovich, D.I. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205:2235–2249.
   PubMed Web of Science ®Google Scholar
• Chioda, M., Peranzoni, E., Desantis, G., Papalini, F., Falisi, E., Solito, S., Mandruzzato, S., and Bronte, V. (2011). Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev. 30:27–43.
   Google Scholar
• Choi, J., Suh, B., Ahn, Y.O., Kim, T.M., Lee, J.O., Lee, S.H., and Heo, D.S. (2012). CD15(+) /CD16 (low) human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol. 33:121–129.
   PubMedGoogle Scholar
• Curran, C.S., Evans, M.D., and Bertics, P.J. (2011). GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J. Immunol. 187:1254–1263.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero, C.M., Salem, M.L., Nishimura, M.I., Garrett-Mayer, E., Cole, D.J., and Montero, A.J. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49–59.
   PubMed Web of Science ®Google Scholar
• Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., Grassi, F., and Bronte, V. (2010). Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:22–35.
   PubMed Web of Science ®Google Scholar
• Ezernitchi, A.V., Vaknin, I., Cohen-Daniel, L., Levy, O., Manaster, E., Halabi, A., Pikarsky, E, Shapira, L., and Baniyash, M. (2006). TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177:4763–4772.
   PubMed Web of Science ®Google Scholar
• Filipazzi, P., Huber, V., and Rivoltini, L. (2012). Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61:255–263.
   PubMed Web of Science ®Google Scholar
• Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., and Rivoltini, L. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25:2546–2553.
   PubMed Web of Science ®Google Scholar
• Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., and Cohen, P. (2011). MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11:856–861.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D.P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D.I., Bronte, V., Chen, S.H., Colombo, M.P., Ochoa, A., Ostrand-Rosenberg, S., and Schreiber, H. (2007). The terminology issue for myeloid-derived suppressor cells. Cancer Res 67:425; author reply 426.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162–174.
   PubMed Web of Science ®Google Scholar
• Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., Bicciato, S., and Bronte, V. (2006). Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116:2777–2790.
   PubMed Web of Science ®Google Scholar
• Hanson, E.M., Clements, V.K., Sinha, P., Ilkovitch, D., and Ostrand-Rosenberg, S. (2009). Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183:937–944.
   PubMed Web of Science ®Google Scholar
• Heikkila, K., Ebrahim, S., and Lawlor, D.A. (2008). Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 44:937–945.
   PubMed Web of Science ®Google Scholar
• Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E, Bromberg, J., Divino, C.M., and Chen, S.H. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123–1131.
   PubMed Web of Science ®Google Scholar
• Ilkovitch, D., and Lopez, D.M. (2009). The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 69:5514–5521.
   PubMed Web of Science ®Google Scholar
• Kuang, D.M., Zhao, Q., Xu, J., Yun, J.P., Wu, C., and Zheng, L. (2008). Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J. Immunol. 181:3089–3098.
   PubMed Web of Science ®Google Scholar
• Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kubler, H., Yancey, D., Dahm, P., and Vieweg, J. (2008). Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14:8270–8278.
   PubMed Web of Science ®Google Scholar
• Lechner, M.G., Liebertz, D.J., and Epstein, A.L. (2010). Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185:2273–2284.
   PubMed Web of Science ®Google Scholar
• Lechner, M.G., Megiel, C., Russell, S.M., Bingham, B., Arger, N., Woo, T., and Epstein, A.L. (2011). Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9:90.
   PubMed Web of Science ®Google Scholar
• Li, H., Han, Y., Guo, Q., Zhang, M., and Cao, X. (2009). Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182:240–249.
   PubMed Web of Science ®Google Scholar
• Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C.R., Nitti, D., Bronte, V., and Zanovello, P. (2009). IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:6562–6568.
   PubMed Web of Science ®Google Scholar
• Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., Calabrese, F., Basso, G., Zanovello, P., Cozzi, E., Mandruzzato, S. and Bronte, V. (2010). Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32:790–802.
   PubMed Web of Science ®Google Scholar
• Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K., Koutoulaki, A., Gerard, C., Coukos, G., and Lambris, J.D. (2008/0. Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235.
   PubMed Web of Science ®Google Scholar
• McKenna, K.C., Beatty, K.M., Bilonick, R.A., Schoenfield, L., Lathrop, K.L., and Singh, A.D. (2009). Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest. Ophthalmol. Vis. Sci. 50:4295–4303.
   PubMed Web of Science ®Google Scholar
• Meyer, C., Sevko, A., Ramacher, M., Bazhin, A.V., Falk, C.S.; Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., and Umansky, V. (2011). Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108:17111–17116.
   PubMed Web of Science ®Google Scholar
• Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., and Shiina, M. (2012). IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 122:143–159.
   PubMed Web of Science ®Google Scholar
• Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., Savino, B., Colombo, P., Jonjic, N., Pecanic, S., Lazzarato, L., Fruttero, R., Gasco, A., Bronte, V., and Viola, A. (2011). Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208:1949–1962.
   PubMed Web of Science ®Google Scholar
• Montero, A.J., Diaz-Montero, C.M., Kyriakopoulos, C.E., Bronte, V., and Mandruzzato, S. (2012). Myeloid-derived suppressor cells in cancer patients: A clinical perspective. J. Immunother. 35:107–115.
   PubMed Web of Science ®Google Scholar
• Monti, F., Szymczuk, S., Motta, M.R., Benini, C., Fattori, P.P., Pini, E., Pasquini, E., Zoli, W., Amadori, D., and Ravaioli, A. (1993). GM-CSF production in human adenocarcinoma cell lines. J. Biol. Regul. Homeost. Agents 7:85–91.
   PubMed Web of Science ®Google Scholar
• Morales, J.K., Kmieciak, M., Knutson, K.L., Bear, H.D., and Manjili. M.H. (2010). GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123:39–49.
   PubMed Web of Science ®Google Scholar
• Nagaraj, S., Gupta, K.,Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D.L., Schneck, J., Gabrilovich, D.I. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828–835.
   PubMed Web of Science ®Google Scholar
• Nagaraj, S., Nelson, A., Youn, J.I., Cheng, P., Quiceno, D., and Gabrilovich, D.I. (2012). Antigen-specific CD4+ T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res
   Google Scholar
• Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R.P., and Kalinski, P. (2011). PGE2-Induced CXCL12 Production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71:7463–7470.
   PubMed Web of Science ®Google Scholar
• Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., and Saito, T. (1996). Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA 93:13119–13124.
   PubMed Web of Science ®Google Scholar
• Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M.P., and Rivoltini, L. (2007). Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18:226–232.
   PubMed Web of Science ®Google Scholar
• Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., and Bronte, V. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238–244.
   PubMed Web of Science ®Google Scholar
• Poschke, I., D. Mougiakakos, J. Hansson, G.V. Masucci, and R. Kiessling. 2010. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335–4345.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Ernstoff, M.S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., and Ochoa, A.C. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553–1560.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., and Ochoa, A.C. (2008). Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222:180–191.
   PubMed Web of Science ®Google Scholar
• Rokhlin, O.W., Griebling, T.L., Karassina, N.V., Raines, M.A., and Cohen, M.B. (1996). Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface. Anticancer Res. 16:557–563.
   PubMed Web of Science ®Google Scholar
• Schule, J., Bergkvist, L., Hakansson, L., Gustafsson, B., and Hakansson, A. (2002). Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res. Treat. 74:33–40.
   PubMed Web of Science ®Google Scholar
• Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., and Borrello, I. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203:2691–2702.
   PubMed Web of Science ®Google Scholar
• Serafini, P., Mgebroff, S., Noonan, K., and Borrello, I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439–5449.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Chornoguz, O., Clements, V.K., Artemenko, K.A., Zubarev, R.A., and Ostrand-Rosenberg, S. (2011). Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117:5381–5390.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Clements, V.K., Fulton, A.M., and Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67:4507–4513.
   PubMed Web of Science ®Google Scholar
• Solito, S., Bronte, V., and Mandruzzato, S. (2011a). Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 90:31–36.
   PubMed Web of Science ®Google Scholar
• Solito, S., Falisi, E., Diaz-Montero, C.M., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Onicescu, G., Garrett-Mayer, E., Montero, A.J., Bronte, V., and Mandruzzato, S. (2011b). A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118:2254–2265.
   PubMed Web of Science ®Google Scholar
• Sonda, N., Chioda, M., Zilio, S., Simonato, F., and Bronte, V. (2011). Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 23:279–285.
   PubMed Web of Science ®Google Scholar
• Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C.A., Voronov, E., and Apte, R.N. (2005). CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175:8200–8208.
   PubMed Web of Science ®Google Scholar
• Srivastava, M.K., Bosch, J.J., Thompson, J.A., Ksander, B.R., Edelman, M.J., and Ostrand-Rosenberg, S. (2008). Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57:1493–1504.
   PubMed Web of Science ®Google Scholar
• Srivastava, M.K., Sinha, P.. Clements, V.K., Rodriguez, P., and Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68–77.
   PubMed Web of Science ®Google Scholar
• Stepkowski, S.M., Chen, W., Ross, J.A., Nagy, Z.S., and Kirken, R.A. (2008). STAT3: an important regulator of multiple cytokine functions. Transplantation 85:1372–1377.
   Google Scholar
• Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., and Bronte, V. (2009). Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9:470–481.
   PubMed Web of Science ®Google Scholar
• Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rebe, C., and Ghiringhelli, F. (2010). 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061.
   PubMed Web of Science ®Google Scholar
• Waight, J.D., Hu, Q., Miller, A., Liu, S., and Abrams, S.I. (2011). Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6:e27690.
   PubMed Web of Science ®Google Scholar
• Youn, J.I., and Gabrilovich, D.L. (2010). The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40:2969–2975.
   PubMed Web of Science ®Google Scholar
• Yuan, X.K., X.K. Zhao, Y.C. Xia, X. Zhu, and P. Xiao. 2011. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J. Int. Med. Res. 39:1381–1391.
   PubMed Web of Science ®Google Scholar
• Zea, A.H., Rodriguez, P.C., Atkins, M.B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O’Neill, A., Mier, J., and Ochoa, A.C. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044–3048.
   PubMed Web of Science ®Google Scholar